**Pseudomonas aeruginosa Keratitis: Outcomes and Response to Corticosteroid Treatment**

Aileen Sy,1 Muthiah Srinivasan,2 Jeena Mascarenhas,2 Prajna Lalitha,2 Revathi Rajaraman,3 Meenakshi Ravindran,4 Catherine E. Oldenburg,1 Kathryn J. Ray,1 David Glidden,5 Michael E. Zegans,6,7 Stephen D. McLeod,1,8 Thomas M. Lietman,1,5,8 and Nisha R. Acharya1,8

**PURPOSE.** To compare the clinical course and effect of adjunctive corticosteroid therapy in *Pseudomonas aeruginosa* with those of all other strains of bacterial keratitis.

**METHODS.** Subanalyses were performed on data collected in the Steroids for Corneal Ulcers Trial (SCUT), a large randomized controlled trial in which patients were treated with moxifloxacin and were randomly assigned to 1 of 2 adjunctive treatment arms: corticosteroid or placebo (4 times a day with subsequent reduction). Multivariate analysis was used to determine the effect of predictors, organism, and treatment on outcomes, 3-month best-spectacle-corrected visual acuity (BSCVA), and infiltrate/scar size. The incidence of adverse events over a 3-month follow-up period was compared using Fisher’s exact test.

**RESULTS.** SCUT enrolled 500 patients. One hundred ten patients had *P. aeruginosa* ulcers; 99 of 110 (90%) enrolled patients returned for follow-up at 3 months. Patients with *P. aeruginosa* ulcers had significantly worse visual acuities than patients with other bacterial ulcers (*P = 0.001*) but showed significantly more improvement in 3-month BSCVA than those with other bacterial ulcers, adjusting for baseline characteristics (−0.14 logMAR, 95% confidence interval, −0.23 to −0.04; *P = 0.004*). There was no significant difference in adverse events between *P. aeruginosa* and other bacterial ulcers. There were no significant differences in BSCVA (*P = 0.69*), infiltrate/scar size (*P = 0.17*), and incidence of adverse events between patients with *P. aeruginosa* ulcers treated with adjunctive corticosteroids and patients given placebo.

**CONCLUSIONS.** Although *P. aeruginosa* corneal ulcers have a more severe presentation, they appear to respond better to treatment than other bacterial ulcers. The authors did not find a significant benefit with corticosteroid treatment, but they also did not find any increase in adverse events. (ClinicalTrials.gov number, NCT00324168.) (Invest Ophtalmol Vis Sci. 2012;53:267–272) DOI:10.1167/iovs.11-7840

Among the causative organisms of bacterial keratitis, *Pseudomonas aeruginosa* is of particular concern for several reasons. *P. aeruginosa*, which causes a significant proportion of bacterial keratitis, is responsible for 6% to 39% of cases in the United States and 8% to 21% in South India.1,7 Additionally, *P. aeruginosa* corneal ulcers have been described as more severe at presentation than other bacterial corneal ulcers.1,8–10 *P. aeruginosa* is also known to be highly virulent, and *P. aeruginosa* ulcers are generally thought to be more difficult to treat and to result in worse visual outcomes than other bacterial corneal ulcers.1,8–10 Lastly, there is particular concern regarding the use of corticosteroids in the treatment of *P. aeruginosa* corneal ulcers. Animal studies have described increased rates of recurrence in *P. aeruginosa* ulcers treated with corticosteroids compared with other bacterial ulcers treated with corticosteroids.11,12 In a recent pair of editorials, one author advised readers to be “especially cautious” when considering corticosteroids for *P. aeruginosa* ulcers.13 A second stated the “prevailing bias against using topical corticosteroids in *P. aeruginosa* keratitis was based on ‘inconclusive’ evidence.”14 Previous clinical trials investigating corticosteroid use in bacterial keratitis have not had enough power to detect a significant effect of corticosteroids and have only had a few cases of *P. aeruginosa* ulcers.15–17 More recently, the Steroids for Corneal Ulcers Trial (SCUT), a large randomized controlled trial, demonstrated no overall difference in visual outcomes with adjunctive corticosteroid use in bacterial corneal ulcers.18 In this study, we perform subgroup analyses of SCUT to better characterize the clinical course of *P. aeruginosa* corneal ulcers and to determine the effect of topical corticosteroid therapy on their outcomes.

**METHODS**

SCUT was a National Institutes of Health–funded randomized, double-masked, placebo-controlled, multicenter clinical trial with two parallel arms comparing adjunctive topical prednisolone phosphate 1% (Bausch & Lomb Pharmaceuticals, Inc., Tampa, FL) with topical placebo (NaCl 0.9% and preservative, prepared by Leiter’s Pharmacy, San Jose, CA); all patients received topical moxifloxacin 0.5% (Viangnox, Alcon, Fort Worth, TX). Specific methods of the trial have been de-

---

From the 1F. I. Proctor Foundation and the Department of Ophthalmology and Biostatistics and 8Ophthalmology, University of California, San Francisco, San Francisco, California; 2Aravind Eye Care System, Madurai, India; 3Aravind Eye Care System, Coimbatore, India; 4Aravind Eye Care System, Tirunelveli, India; and the Departments of Surgery (Ophthalmology) and Microbiology and Immunology, Dartmouth Medical School, Lebanon, New Hampshire.

Supported by National Eye Institute Grants U10 EY015114 (SCUT) and K23EY017897 (NRA) and Core Grant EY02162; a Research to Prevent Blindness Award (NRA); the Proctor Foundation (AS); an Institutional Research Fellowship from the UCSF School of Medicine (AS); a Pathways to Careers in Clinical and Translational Research Fellowship (NIH/NCRR/OD UCSF-CTSI Grant Number TL1 RR024129) (AS); CoreGrantEY02162; a Research to Prevent Blindness Award (NRA); the Proctor Foundation (AS); an Institutional Research Fellowship from the UCSF School of Medicine (AS); a Pathways to Careers in Clinical and Translational Research Fellowship (NIH/NCRR/OD UCSF-CTSI Grant Number TL1 RR024129) (AS); an unrestricted grant from Research to Prevent Blindness; and That Man May See.

Submitted for publication May 6, 2011; revised August 19, October 9, and November 13, 2011; accepted November 22, 2011.

Disclosure: A. Sy, None; M. Srinivasan, None; J. Mascarenhas, None; P. Lalitha, None; R. Rajaraman, None; M. Ravindran, None; C.E. Oldenburg, None; K.J. Ray, None; D. Glidden, None; M.E. Zegans, None; S.D. McLeod, None; T.M. Lietman, None; N.R. Acharya, None.

Corresponding author: Nisha R. Acharya, F. I. Proctor Foundation, Room S309, 513 Parnassus Avenue, University of California, San Francisco, San Francisco, CA 94143-0412; nisha.acharya@ucsf.edu.

Copyright 2012 The Association for Research in Vision and Ophthalmology, Inc.
corticosteroid therapy in ulcers caused by
cluded subgroup analyses comparing the overall efficacy and safety of
apy improves visual outcomes of bacterial corneal ulcers as measured
trial was to determine whether adjunctive topical corticosteroid ther-
drop 4 times a day for the first week after enrollment, then twice daily
started 48 hours after moxifloxacin therapy and was administered 1
3 weeks from enrollment. Topical corticosteroid or placebo was
drop every 2 hours until reepithelialization, and then 4 times a day until
Corneal ulcer (defined as presence of descemetocele).
Growth of organism on one solid medium at the site of inoculation was
and were cultured on sheep's blood agar, chocolate agar, and potato dextrose agar or Sabouraud's agar for bacterial and fungal cultures.
Growth of organism on one solid medium at the site of inoculation was considered a positive bacterial culture except for coagulase-negative
Staphylococcus and diphtheroid bacteria, in which moderate growth
on at least two solid media or on one solid medium with appropriate morphology and staining characteristics on Gram's stain was needed. Exclusion criteria included evidence of fungus, acanthamoeba or her-
pes virus infection, any use of topical corticosteroids before presenta-
tion, bilateral ulcers, best spectacle-corrected visual acuity (BSCVA) worse than 6/60 in the fellow eye, no light perception in the affected
eye, age younger than 16 years, and impending perforation of the
corneal ulcer (defined as presence of descemetocele).
Moxifloxacin, administered to both treatment arms, was adminis-
tered as 1 drop every hour while awake for the first 48 hours, then 1
drop every 2 hours until reepithelialization, and then 4 times a day until
3 weeks from enrollment. Topical corticosteroid or placebo was
started 48 hours after moxifloxacin therapy and was administered 1
drop 4 times a day for the first week after enrollment, then twice daily
for 1 week, and then once a day for 1 week. The primary aim of the trial was to determine whether adjunctive topical corticosteroid ther-
apy improves visual outcomes of bacterial corneal ulcers as measured
by BSCVA 3 months after enrollment. Prespecified secondary out-
comes included infiltrate/scar size at 3 months, time to reepithelializa-
tion, and adverse events. Additional prespecified aims of SCUT in-
cluded subgroup analyses comparing the overall efficacy and safety of
corticosteroid therapy in ulcers caused by P. aeruginosa versus other
bacteria and any difference in efficacy based on enrollment character-
istics.
Patients were evaluated at baseline, every 3 days (≥1 day) until
reepithelialization (defined as epithelial defect ≤0.5 mm), at 3 weeks,
and at 3 months by certified, masked refractionists and ophthalmolo-
gists who conducted visual acuity examinations and slit lamp exami-
nations. LogMAR visual acuity was measured by tumbling “E” charts at
4 meters (Charts 2305 and 2305A; Precision Vision, La Salle, IL). Using
a slit lamp, infiltrate/scar size was measured as the longest dimension
and the longest perpendicular to this dimension in millimeters.
Informed consent was obtained for all subjects enrolled in SCUT.
Institutional Review Board approval was granted by the Aravind Eye
Care System Institutional Review Board, the University of California,
San Francisco Committee on Human Research, and the Dartmouth-
Hitchcock Medical Center Committee for Protection of Human Sub-
jects. This study adhered to the tenets of the Declaration of Helsinki.

Statistical Methods
This study performed subanalyses on all patients in SCUT except mixed bacterial infections (two or more distinct bacterial organisms on
culture at enrollment). Baseline demographic features and risk factors for P. aeruginosa ulcers were compared with those of all other
bacterial ulcers and were analyzed by treatment group using the
Fishier's exact test for categorical variables and the Wilcoxon rank-sum
test for continuous variables. BSCVA (logMAR) and infiltrate/scar size
(mm) of P. aeruginosa versus all other bacteria ulcers were compared at baseline and at 3 months using linear regression analysis. To assess
the response to treatment of P. aeruginosa versus other bacterial
organisms of similar presentation, a prespecified multiple linear regression model including a dichotomous term of P. aeruginosa versus all
other bacteria (the predictor of interest), treatment arm, and enroll-
ment characteristics (BSCVA or infiltrate/scar size) as covariates was used to predict both BSCVA (logMAR) and infiltrate/scar size (geomet-
ric mean of the two measurements in mm) at enrollment and 3 months. To test for a possible differential effect of corticosteroid treatment on
P. aeruginosa ulcers, an interaction term (organism × treatment) was
added to our model. Sensitivity analysis including treatment arm and
enrollment BSCVA, scar size, ulcer depth, and ulcer location as coava-
riates was used to assess for confounders. Sensitivity analyses were also
performed to test for effects of study site, examiner, mixed infections, and nonlinear distribution of baseline visual acuity. Comparison of
adverse events including perforation, elevated intraocular pressure
(IOP), and recurrence of epithelial defect (defined as resolution of the
epithelial defect ≤0.5 mm followed by new epithelial defect ≥1 mm)
between P. aeruginosa and all other bacteria was performed using the
fisher's exact test. Within the P. aeruginosa subgroup, time to reepi-
thelialization analyses comparing corticosteroid and placebo arms
were conducted using Cox proportional hazards regression. The inci-
dence of adverse events in each of the treatment arms of the P.
aeruginosa subgroup was compared using the Fisher's exact test. Multivariate regression models were used to test for differing effects of
corticosteroids on outcomes of BSCVA and infiltrate/scar size at 3
months by subgroups of baseline visual acuity, infiltrate size, ulcer
depth, and location. All analyses were performed using statistical
analysis software (Stata 10; StatCorp, College Station, TX). Negative
logMAR values indicate improvement in visual acuity, and negative
infiltrate/scar size values indicate decreases in infiltrate/scar size. P
values reported are nominal values and have not been adjusted for
multiple comparisons.

RESULTS
Among the 500 patients enrolled in SCUT, the most common
organisms isolated were Streptococcus pneumoniae, P. aeruginosa, and Nocardia spp. Six patients were excluded
from analysis because they had mixed bacterial infections; one of
these was a mixed P. aeruginosa and S. pneumoniae
infection. This left 494 patients for analysis comparing the P.
aeruginosa (110 patients with all other bacteria (384 pa-
tients) (Table 1). Of 110 P. aeruginosa patients, 105 were from
India and 5 were from the United States. Among patients with
P. aeruginosa ulcers, 10% were lost to follow-up at 3 months in
both the corticosteroid (53/59) and the placebo (46/51)
treatment arms (P > 0.99). Within the P. aeruginosa sub-
group, the median enrollment BSCVA in the corticosteroid
group was 1.50 logMAR (approximate Snellen equivalent 20/
640); the median enrollment BSCVA in the placebo group was
1.12 logMAR (Snellen equivalent 20/250, P = 0.10). There
were no significant differences in baseline demographic features
and clinical examination findings between the two treat-
ment arms of the P. aeruginosa subgroup (Table 2).
Patients with P. aeruginosa ulcers presented with signifi-
cantly worse visual acuities than did patients with other bac-
terial ulcers (0.24 logMAR [−2.5 lines difference]; 95% confi-
dence interval [CI], 0.10–0.38; P = 0.001; Fig. 1). However,
multiple linear regression analysis adjusting for enrollment
characteristics showed P. aeruginosa ulcers to show signifi-
cantly greater improvement in visual acuity at 3 months than
other bacterial ulcers of similar presentation severity (−0.14
logMAR [−1.5 lines]; 95% CI, −0.23 to −0.04; P = 0.004; Table 3). As a result, there was no significant difference
in 3-month BSCVA between P. aeruginosa ulcers and all other
bacterial ulcers (0.01 logMAR [−0.1 line difference]; 95% CI,
−0.12 to 0.14; P = 0.87; Fig. 1). Sensitivity analyses supported
this finding and demonstrated that infiltrate/scar size, depth,
and location were not confounders. Sensitivity analysis also
demonstrated that study site, examiner, inclusion of mixed
infections, and nonlinear distribution of baseline visual acuity
did not affect outcomes. Multiple linear regression including
enrollment characteristics did not find a significant difference

268 Sy et al. IJOVS, January 2012, Vol. 53, No. 1
in the geometric mean of infiltrate/scar size between *P. aeruginosa* ulcers and other bacterial ulcers at 3 months (H11002 0.07 mm; 95% CI, 0.23 to 0.09; *P* 0.40; Table 3). There was no significant difference in rates of adverse events between *P. aeruginosa* and all other bacteria (regardless of treatment arm), including corneal perforation (*P* 0.54) and recurrence of epithelial defect (*P* 0.69; Table 4).

Corticosteroid effects on visual outcomes were compared between patients with and without *P. aeruginosa* infection, with a −0.04 logMAR (95% CI, −0.21 to 0.13) change at 3 months for those with *P. aeruginosa* ulcers and a −0.003 logMAR (95% CI, −0.09 to 0.08) change at 3 months for those with all other bacterial ulcers. The difference in response to corticosteroid treatment between *P. aeruginosa* and all other

### Table 1. Baseline Characteristics of Patients in SCUT: Comparison between *P. aeruginosa* and All Other Bacterial Ulcers

<table>
<thead>
<tr>
<th></th>
<th><em>P. aeruginosa</em> (n = 110)</th>
<th>All Other Bacteria* (n = 384)</th>
<th><em>P</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years, median (IQR)</td>
<td>43 (30–54)</td>
<td>55 (42.5–63)</td>
<td>&lt;0.001†</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
<td>0.051‡</td>
</tr>
<tr>
<td>Male</td>
<td>69 (65)</td>
<td>199 (52)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>41 (37)</td>
<td>185 (48)</td>
<td></td>
</tr>
<tr>
<td>Duration of symptoms, n (%)</td>
<td></td>
<td></td>
<td>0.008‡</td>
</tr>
<tr>
<td>&lt;4 days</td>
<td>55 (50)</td>
<td>144 (38)</td>
<td></td>
</tr>
<tr>
<td>4–7 days</td>
<td>42 (38)</td>
<td>151 (39)</td>
<td></td>
</tr>
<tr>
<td>8–14 days</td>
<td>10 (9)</td>
<td>44 (31)</td>
<td></td>
</tr>
<tr>
<td>&gt;14 days</td>
<td>3 (3)</td>
<td>45 (12)</td>
<td></td>
</tr>
<tr>
<td>Contact lens use, n (%)</td>
<td>7 (6)</td>
<td>1 (0.2)</td>
<td>0.001‡</td>
</tr>
<tr>
<td>Systemic disease, n (%)</td>
<td>6 (5)</td>
<td>21 (5)</td>
<td>&gt;0.99‡</td>
</tr>
<tr>
<td>Ulcer location, n (%)</td>
<td></td>
<td></td>
<td>0.007‡</td>
</tr>
<tr>
<td>Entirely in periphery</td>
<td>9 (8)</td>
<td>56 (15)</td>
<td></td>
</tr>
<tr>
<td>Partially covering 4 mm</td>
<td>65 (59)</td>
<td>253 (66)</td>
<td></td>
</tr>
<tr>
<td>Completely fills 4 mm</td>
<td>36 (33)</td>
<td>73 (19)</td>
<td></td>
</tr>
<tr>
<td>Visual acuity, logMAR, median (IQR)</td>
<td>1.26 (0.46–1.7)</td>
<td>0.74 (0.35–1.6)</td>
<td>0.002†</td>
</tr>
<tr>
<td>Infiltrate/scar size in mm, median (IQR)</td>
<td>3.8 (2.5–5.6)</td>
<td>2.5 (1.8–3.7)</td>
<td>&lt;0.001†</td>
</tr>
<tr>
<td>Treatment arm, n (%)</td>
<td></td>
<td></td>
<td>0.45‡</td>
</tr>
<tr>
<td>Corticosteroid</td>
<td>59 (54)</td>
<td>188 (49)</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>51 (46)</td>
<td>196 (51)</td>
<td></td>
</tr>
</tbody>
</table>

* Other bacteria include *Streptococcus pneumoniae* (n = 250), *Nocardia* spp. (n = 56), coagulase-negative *Staphylococcus* (n = 22), *Staphylococcus aureus* (n = 16), *Moraxella* spp. (n = 15), Viridans group *Streptococcus* (n = 11), *Corynebacterium* spp. (n = 6), *Bacillus* spp. (n = 1), *Mycobacteria* spp. (n = 1), *Klebsiella* spp. (n = 3), *Enterobacter* spp. (n = 2), *Haemophilus influenzae* (n = 1), other *Pseudomonas* spp. (non-*Aeruginosa*, n = 5), other Gram-positive (n = 5), and Gram-negative bacteria (n = 5).

† Rank sum test.
‡ Fisher’s exact test.
§ Systemic diseases included diabetes, asthma, Hansen’s disease, eczema, psoriasis, HIV, ichthyosis, and malnutrition.

### Table 2. Baseline Characteristics of Patients from SCUT with *P. aeruginosa* Corneal Ulcers: Comparison between Corticosteroid and Placebo Treatment Arms

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n = 51)</th>
<th>Corticosteroid (n = 59)</th>
<th><em>P</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years, median (IQR)</td>
<td>41 (30–50)</td>
<td>45 (30–56)</td>
<td>0.39*</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
<td>0.44†</td>
</tr>
<tr>
<td>Male</td>
<td>34 (67)</td>
<td>35 (59)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>17 (33)</td>
<td>24 (41)</td>
<td></td>
</tr>
<tr>
<td>Duration of symptoms, n (%)</td>
<td></td>
<td></td>
<td>0.71†</td>
</tr>
<tr>
<td>&lt;4 days</td>
<td>27 (53)</td>
<td>28 (47)</td>
<td></td>
</tr>
<tr>
<td>4–7 days</td>
<td>20 (39)</td>
<td>22 (37)</td>
<td></td>
</tr>
<tr>
<td>8–14 days</td>
<td>3 (6)</td>
<td>7 (12)</td>
<td></td>
</tr>
<tr>
<td>&gt;14 days</td>
<td>1 (2)</td>
<td>2 (3)</td>
<td></td>
</tr>
<tr>
<td>Contact lens use, n (%)</td>
<td>4 (8)</td>
<td>4 (7)</td>
<td>&gt;0.99†</td>
</tr>
<tr>
<td>Systemic disease, n (%)‡</td>
<td>4 (8)</td>
<td>2 (3)</td>
<td>0.41†</td>
</tr>
<tr>
<td>Ulcer location, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Entirely in periphery</td>
<td>4 (8)</td>
<td>5 (8)</td>
<td>0.15†</td>
</tr>
<tr>
<td>Partially covering 4 mm</td>
<td>35 (69)</td>
<td>30 (51)</td>
<td></td>
</tr>
<tr>
<td>Completely fills 4 mm</td>
<td>12 (24)</td>
<td>24 (41)</td>
<td></td>
</tr>
<tr>
<td>Visual acuity, logMAR, median (IQR)</td>
<td>1.12 (0.46–1.7)</td>
<td>1.50 (0.46–1.8)</td>
<td>0.10*</td>
</tr>
<tr>
<td>Infiltrate/scar size in mm, median (IQR)</td>
<td>3.75 (2.4–5.5)</td>
<td>3.75 (2.7–5.5)</td>
<td>0.29*</td>
</tr>
</tbody>
</table>

* Rank sum test.
† Fisher’s exact test.
‡ Systemic diseases included diabetes, asthma, Hansen’s disease, eczema, psoriasis, HIV, ichthyosis, and malnutrition.
bacterial ulcers was not significant (−0.04 logMAR [−0.5 line]; 95% CI, −0.38 to 0.15; \( P = 0.69 \)). For infiltrate/scar size at 3 months, corticosteroids contributed to a −0.11 mm (95% CI, −0.38 to 0.15) change in \( P. \) aeruginosa ulcers and a 0.10 mm (95% CI, −0.04 to 0.26) change in all other bacterial ulcers; the difference in response to corticosteroid treatment between \( P. \) aeruginosa and all other bacterial ulcers was not significant (−0.21 mm; 95% CI, −0.51 to 0.09; \( P = 0.17 \)). Within the \( P. \) aeruginosa subgroup, there were more changes or additions of antibiotics in the placebo group than in the corticosteroid group (Table 5). There was no evidence of any other difference in incidence of adverse events over a 3-month follow-up period between the corticosteroid and the placebo groups of the \( P. \) aeruginosa subgroup, including corneal perforations, increased IOP, recurrence of epithelial defect, and delay in epithelial defect resolution (Table 5). The median time to reepithelialization was 9.5 days (interquartile range [IQR]: 4, 20) in the corticosteroid group and 7.0 days (IQR: 3, 15) in the placebo group. Kaplan-Meier curves showed that the corticosteroid group had slower reepithelialization than the placebo group (Fig. 2), but the difference in time to reepithelialization was not statistically significant (\( P = 0.22 \)). Prespecified subgroup analyses based on enrollment characteristics (including enrollment visual acuity, infiltrate/scar size, ulcer location, and depth of defect) did not find any significant effect of corticosteroid treatment on primary or secondary outcomes.

### Table 3. Comparison of Visual Acuity and Infiltrate/Scar Size Outcomes between \( P. \) aeruginosa and All Other Bacterial Ulcers

<table>
<thead>
<tr>
<th>Covariate</th>
<th>Coefficient (95% CI)</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linear regression predicting 3-month logMAR BSCVA (( n = 438 ))</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enrollment BSCVA</td>
<td>0.64 (0.58 to 0.70)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Corticosteroid treatment</td>
<td>−0.01 (−0.09 to 0.07)</td>
<td>0.79</td>
</tr>
<tr>
<td>Bacterial type (( P. ) aeruginosa vs. other)</td>
<td>−0.14 (−0.23 to −0.04)</td>
<td>0.004</td>
</tr>
<tr>
<td>Constant</td>
<td>−0.07 (−0.15 to 0.01)</td>
<td>0.07</td>
</tr>
<tr>
<td>Linear regression predicting 3-month infiltrate/scar size in mm (( n = 436 ))</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enrollment infiltrate/scar size</td>
<td>0.92 (0.88 to 0.96)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Corticosteroid treatment</td>
<td>0.05 (0.07 to 0.17)</td>
<td>0.41</td>
</tr>
<tr>
<td>Bacterial type (( P. ) aeruginosa vs. other)</td>
<td>−0.07 (−0.23 to 0.09)</td>
<td>0.40</td>
</tr>
<tr>
<td>Constant</td>
<td>0.17 (0.03 to 0.31)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

### DISCUSSION

\( P. \) aeruginosa ulcers are often thought to respond poorly to treatment and have worse clinical outcomes than other bacterial ulcers.\(^1,9,10\) However, in this subanalysis of a large clinical trial, we found that, when compared with other bacterial ulcers of the same presentation severity, \( P. \) aeruginosa corneal ulcers responded significantly better to treatment, with approximately 1.5 lines greater improvement in visual acuity from presentation to 3-month follow-up that was not attributable to ulcer enrollment characteristics (BSCVA, infiltrate/scar size, depth, and location). In fact, even though they have significantly worse clinical presentations, \( P. \) aeruginosa ulcers do not have significantly worse overall visual outcomes at 3 months when compared with all other bacterial ulcers. There was also no evidence of a significant difference in adverse events between \( P. \) aeruginosa ulcers and other bacterial ulcers, including perforations. These findings suggest that \( P. \) aeruginosa ulcers may not be as difficult to treat or may not result in worse clinical outcomes, as had been previously thought.

The use of adjunctive corticosteroid therapy is particularly controversial for \( P. \) aeruginosa corneal ulcers. Corticosteroids have been shown to reduce the host inflammatory response, which may be damaging to the cornea.\(^1,4,20,21\) However, corticosteroids may also significantly slow the process of corneal wound healing, prolong infection, and predispose to stromal thinning and perforation, especially in \( P. \) aeruginosa infections, which are known to be more invasive and to cause rapid systemic tissue destruction.\(^1,9,10,13,22\) Patients receiving corticosteroid treatment before presentation for corneal infection have been reported to be at triple the risk for complications, including treatment failure.\(^25\) Additionally, animal studies have found corticosteroid treatment in the absence of antibiotic treatment to be associated with increased bacterial growth and recurrence of \( P. \) aeruginosa keratitis in rabbit corneas.\(^11,12\) However, other animal studies have demonstrated that corticosteroid treatment given concurrently with appropriate antibiotic therapy reduces inflammation but does not interfere with the bactericidal action of antibiotics and does not lead to increased bacterial growth.\(^23,24\)

The results of this study indicate there is no significant difference, either benefit or harm, in 3-month BSCVA or infiltrate/scar size among \( P. \) aeruginosa ulcers treated with adjunctive corticosteroids compared with placebo. Although multivariate analysis suggested a slight benefit with corticosteroid treatment over placebo for both 3-month BSCVA and infiltrate/scar size, these findings were not statistically significant. The large number of \( P. \) aeruginosa ulcers from SCUT allowed for the detection of small changes in visual acuity: a priori power calculations estimated ≥80% power to detect approximately a 2-line difference in visual acuity, post hoc, the 95% CI of the interaction term was approximately ±2 lines of visual acuity,

![Figure 1](image-url)  
**Figure 1.** Visual acuity comparison of \( P. \) aeruginosa and all other bacterial ulcers at enrollment and 3 months. The line in the middle of each box represents the median, and the lower and upper bounds of the box represent the 25th and 75th percentiles, the span of which is the interquartile range (IQR). Whiskers extend to the lowest data point within 1.5× IQR below the 25th percentile and to the highest data point within 1.5× IQR above the 75th percentile. Individually plotted points represent outliers or values falling outside the whiskers. \( P \) values were obtained by rank sum test.
suggesting that a large true effect would not be missed. Subgroup analysis did not find any differential effect for corticosteroid efficacy dependent on baseline clinical characteristics.

This study also found no evidence of an increase in adverse events with corticosteroid treatment. Corneal perforation, increased intraocular pressure, and delayed corneal healing are recognized potential adverse events associated with corticosteroid therapy, particularly in \textit{P. aeruginosa} infections. 1,5–12,22 One previous prospective study was discontinued after a patient with a \textit{P. aeruginosa} ulcer worsened following the addition of corticosteroid treatment and required a penetrating keratoplasty for a large central scar. 13 However, we found no difference in the number of perforations between corticosteroid and placebo-treated \textit{P. aeruginosa} ulcers with one patient in each treatment arm. Although corticosteroids may increase IOP, patients with \textit{P. aeruginosa} ulcers receiving corticosteroid treatment in SCUT were not more likely to have elevated IOP than those receiving placebo; in fact, there were more patients with elevated IOP in the placebo arm than in the corticosteroid arm. Delayed corneal wound healing is also a recognized potential adverse effect of corticosteroid therapy. 11,12,22 The pilot study for SCUT found adjunctive corticosteroid treatment to be associated with a significant delay in the reepithelialization of corneal ulcers secondary to all bacterial organisms. 17 However, though there were more reported cases of epithelial defects at 21 days and beyond in the corticosteroid arm, time to reepithelialization was not significantly different between the two treatment arms in SCUT. 18 In this substudy, within the \textit{P. aeruginosa} subgroup, there were more patients who had an epithelial defect at 21 days or beyond in the corticosteroid arm than in the placebo arm, but this difference was not statistically significant. Cox regression analysis also demonstrated that time to reepithelialization was not significantly different between the two study arms. Recurrence of epithelial defect can be another measure of corticosteroid effect on corneal healing. Only one patient with a \textit{P. aeruginosa} ulcer experienced a recurrence of epithelial defect. Although this patient was treated with corticosteroids, there was no significant difference between the two treatment arms. Therefore, our present study did not find a significant delay in the measures of healing time and recurrence of epithelial defect for \textit{P. aeruginosa} ulcers treated with corticosteroids.

This study has a few potential limitations. Because most patients were enrolled at the Aravind Eye Care System in India, it is possible that differences in risk factors, bacteriology, and response to treatment in this population may make these results not generalizable to other populations. \textit{P. aeruginosa} infections are most common among contact lens wearers in the United States. 1 In SCUT, although most contact lens wearers had \textit{P. aeruginosa} infection, a low proportion of the total \textit{P. aeruginosa} cases occurred in contact lens wearers because contact lens use is less common in India. 2,19 This difference in associated risk factors may reflect genotypic variation in \textit{P. aeruginosa} strains between the two countries. Variations of pathogenicity between \textit{P. aeruginosa} strains could contribute

### Table 4. Comparison of Adverse Events in \textit{P. aeruginosa} Ulcers versus All Other Bacterial Ulcers

<table>
<thead>
<tr>
<th></th>
<th>\textit{P. aeruginosa} (n = 110)</th>
<th>All Other Bacteria (n = 384)</th>
<th>Total n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in antibiotic/addition of other antibiotic</td>
<td>15 (14)</td>
<td>53 (14)</td>
<td>68 (14)</td>
</tr>
<tr>
<td>Corneal perforation</td>
<td>2 (2)</td>
<td>13 (3)</td>
<td>15 (3)</td>
</tr>
<tr>
<td>Death</td>
<td>2 (2)</td>
<td>10 (3)</td>
<td>12 (2)</td>
</tr>
<tr>
<td>IOP elevated (&gt;25 \text{ but } \leq 35 \text{ mm Hg with medications within 1 week of therapy})†</td>
<td>4 (4)</td>
<td>8 (2)</td>
<td>12 (2)</td>
</tr>
<tr>
<td>Increase in infiltrate size ((&gt;50%)) and (&gt;1 \text{ mm in maximum diameter})</td>
<td>1 (1)</td>
<td>12 (3)</td>
<td>13 (3)</td>
</tr>
<tr>
<td>No resolution of epithelial defect at 21 days or later</td>
<td>19 (17)</td>
<td>52 (14)</td>
<td>71 (14)</td>
</tr>
<tr>
<td>Progressive corneal thinning (\geq 50%) of enrollment thickness</td>
<td>1 (1)</td>
<td>1 (0.3)</td>
<td>2 (0.4)</td>
</tr>
<tr>
<td>Recurrence of epithelial defect</td>
<td>1 (1)</td>
<td>7 (2)</td>
<td>8 (2)</td>
</tr>
<tr>
<td>Total subjects with any adverse events</td>
<td>27 (25)</td>
<td>76 (20)</td>
<td>103 (21)</td>
</tr>
</tbody>
</table>

* Adverse events were recorded from enrollment until the 3-month follow-up. These values (n) reflect the number of cases at enrollment.

† Fisher’s exact test.

‡ IOP elevation \(>35\) was considered a serious adverse event. There were no cases of IOP elevation \(>35\) in SCUT.

### Table 5. Comparison of Adverse Events in Placebo versus Corticosteroid Treatment Arms within the \textit{P. aeruginosa} Subgroup

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n = 51)*</th>
<th>Corticosteroid (n = 59)*</th>
<th>P†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in antibiotic/addition of other antibiotic‡</td>
<td>11 (22)</td>
<td>4 (7)</td>
<td>0.03</td>
</tr>
<tr>
<td>Corneal perforation</td>
<td>1 (2)</td>
<td>1 (2)</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>Death</td>
<td>1 (2)</td>
<td>1 (2)</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>IOP elevated (&gt;25) but (\leq 35) \text{ mm Hg with medications within 1 week of therapy})§</td>
<td>3 (6)</td>
<td>1 (2)</td>
<td>0.34</td>
</tr>
<tr>
<td>Increase in infiltrate size ((&gt;50%)) and (&gt;1 \text{ mm in maximum diameter})</td>
<td>1 (2)</td>
<td>0 (0)</td>
<td>0.46</td>
</tr>
<tr>
<td>No resolution of epithelial defect at 21 days or later</td>
<td>6 (12)</td>
<td>13 (22)</td>
<td>0.21</td>
</tr>
<tr>
<td>Progressive corneal thinning (\geq 50%) of enrollment thickness</td>
<td>1 (2)</td>
<td>0 (0)</td>
<td>0.46</td>
</tr>
<tr>
<td>Recurrence of epithelial defect</td>
<td>0 (0)</td>
<td>1 (2)</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>Total subjects with any adverse events</td>
<td>12 (24)</td>
<td>15 (25)</td>
<td>&gt;0.99</td>
</tr>
</tbody>
</table>

* Adverse events were recorded from enrollment until the 3-month follow-up. These values (n) reflect the number of cases at enrollment.

† Fisher’s exact test.

‡ Other antibiotics included gentamicin, ceftazidime, amikacin, doxycycline, tobramycin, and ciprofloxacin.

§ IOP elevation \(>35\) was considered a serious adverse event. There were no cases of IOP elevation \(>35\) in SCUT.
to differing outcomes and responses to adjunctive cortico-
steroid therapy. Sensitivity analysis demonstrated no effect of
study site on outcome; nevertheless, results may be biased
toward *P. aeruginosa* strains found in India. The SCUT criteria
for a positive bacterial culture, defined as growth of the organ-
ism on one solid medium at the site of inoculation (with more
stringent criteria for coagulase-negative *Staphylococcus* and
diptheroids), may differ from microbiologic criteria in other
studies. The choice of treatment regimen in SCUT, both anti-
biotic and corticosteroid, might also have affected outcomes
because choice of agent, number of agents used, concentra-
tion, and administration timing and route are all factors in
treatment efficacy. Because of potential safety concerns, a
more aggressive corticosteroid regimen was not chosen. The
treating physician did have the option of adding or changing
antibiotics during the trial if deemed necessary. Within the *P.
aeruginosa* subgroup, the number of antibiotic changes was
greater in the placebo treatment arm than in the corticosteroid
treatment arm.

Although *P. aeruginosa* ulcers in SCUT had a more severe
presentation than the other bacterial ulcers, this subanalysis suggests that *P. aeruginosa* ulcers respond better to treatment
than previously thought. There appears to be no definite ben-
efit for visual outcome and infiltrate/scar size with corticoste-
roid treatment in *P. aeruginosa* ulcers. However, the lack of
any significant difference in adverse events with corticosteroid
therapy suggests that adjunctive corticosteroid therapy may be
used according to clinical judgment that takes into account the
specific features of an individual case.

**Acknowledgments**

The authors thank the patients who enrolled in the Steroids for
Corneal Ulcers Trial (SCUT), their families, and the research staffs at all the trial
sites; and Marian Fisher (chair), Anthony Aldave, Donald Everett, Jac-
queline Glover, K. Ananda Kannan, Steven Kymes, Gudalavalli V. S.
Murthy, and Ivan Schwab of the SCUT data and safety monitoring
board for their invaluable guidance and advice.

**References**

1. American Academy of Ophthalmology Cornea/External Disease
Panel. *Bacterial Keratitis: Preferred Practice Pattern*. American

2. Bharathi MJ, Ramakrishnan R, Meenakshi R, Padmavathy S, Shiva-
kumar C, Srinivasan M. Microbial keratitis in South India: influence
of risk factors, climate, and geographical variation. *Ophthalmic

raj D. Etiology and antibacterial susceptibility pattern of commu-
nity-acquired bacterial ocular infections in a tertiary eye care hos-

diagnosis of microbial keratitis in South India—a study of 1618

5. Forster RK, Conrad Berens Lecture: the management of infectious
keratitis as we approach the 21st century. *CLAO J.* 1998;24:175–
180.

6. Srinivasan M, Gonzales CA, George C, et al. Epidemiology and
aetiological diagnosis of corneal ulceration in Madurai, South India.

of infectious corneal ulcers at the F.I. Proctor Foundation. *Cornea.*

8. Green M, Apel A, Stapleton F. Risk factors and causative organisms


10. Pepose JS, Holland GN, Wilhelmus KR. *Ocular Infection and

11. Badenoch PR, Hay GJ, McDonald PJ, Coster DJ. A rat model of
bacterial keratitis: effect of antibiotics and corticosteroid. *Arch

12. Gritz DC, Kwisik T, Trousdale MD, Gonzalez VH, McDonnell PJ.
Recurrence of microbial keratitis concomitant with antiinflamma-

13. Cohen EJ. The case against the use of steroids in the treatment of

14. Hindman HB, Patel SB, Jun AS. Rationale for adjunctive topical
corticosteroids in bacterial keratitis. *Arch Ophthalmol.* 2009;127:
97–102.

and antibiotic-steroid combination treatment in corneal ulcer
patients: double-blinded randomized clinical trial. *Can J Ophthal-
mol.* 2011;46:40–45.

16. Carmichael TR, Geldland Y, Welsh NH. Topical steroids in the
treatment of central and paracentral corneal ulcers. *Br J Ophthal-


bacterial keratitis: The Steroids for Corneal Ulcers Trial (SCUT).

Corneal Ulcers Trial: study design and baseline characteristics.

20. Leibowitz HM, Kuperman A. Anti-inflammatory effectiveness in
the cornea of topicaly administered prednisolone. *Invest Ophthalm-

21. Kuperman A, Leibowitz HM. Anti-inflammatory effectiveness of
topically administered corticosteroids in the cornea without epi-

22. Wilhelmus KR. Indecision about corticosteroids for bacterial
835–842, quiz 843.

23. Hobden JA, Engel LS, Hill JM, Callegan MC, O’Callaghan RJ. Pred-
nisolone acetate or prednisolone phosphate concurrently admin-
istered with ciprofloxacin for the therapy of experimental *Pseu-

24. Engel LS, Callegan MC, Hobden JA, Reidy JJ, Hill JM, O’Callaghan
RJ. Effectiveness of specific antibiotic/steroid combinations for
therapy of experimental *Pseudomonas aeruginosa* keratitis. *Curr

**Figure 2.** Kaplan-Meier curves comparing time to reepithelialization
in corticosteroid versus placebo treatment arms within the *P. aerugi-
nosa* subgroup (n = 110). Curves are right-censored at 21 days; tick
marks represent censoring. One patient in the corticosteroid arm
was censored at day 1; 8 patients in the placebo arm and 14 patients in
the corticosteroid arm were censored at day 21.